At issue is whether the Glaxo drug should stay on the market or be slapped with more stringent warnings or restrictions after the controversial meta-analysis was published in The New England Journal of Medicine. The study set off a firestorm over Glaxo's behavior and a smear campaign against Steve Nissen, the Cleveland Clinic cardiologist who conducted the analysis. Interestingly, the Monday meeting won't incorporate the meta-analysis, because the FDA analysis covers the bases, the agency writes.
You can read the agenda for the Monday meeting here. You can read the committee rosters here, here and here. You can read conflict of interest waivers for committee members here. You can read the FDA briefing document here. And you can read Glaxo's briefing document here.
If this doesn't keep you busy for awhile, what will?